Clinical Trial

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Injection

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HRS-5817 when administered subcutaneously (SC) as single and multiple doses in adults who are affected by obesity.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-11.
Status change: Not Yet Recruiting → Recruiting 2025-11-14
Trial Details
NCT Number NCT06934408
Lead Sponsor Fujian Shengdi Pharmaceutical Co., Ltd.
Conditions Obesity, Overweight
Enrollment 92 participants
Start Date 2025-05-08
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2025-11-17